Johnson & Johnson (JNJ) Capital Expenditures (2009 - 2026)

Johnson & Johnson has disclosed Capital Expenditures across 18 years of filings, most recently posting $1.0 billion for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $1.0 billion, up 31.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.1 billion (up 15.28% YoY), and the FY2025 annual result was $4.8 billion, up 9.22% from the prior year.
• Capital Expenditures came in at $1.0 billion for Q1 2026 at Johnson & Johnson, down from $1.8 billion in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $1.8 billion in Q4 2025 to a low of $607.0 million in Q2 2022.
• The 5-year median for Capital Expenditures is $1.0 billion (2025), against an average of $1.1 billion.
• Across the five-year window, Capital Expenditures jumped 42.17% in 2023 and fell 13.17% in 2024, its largest moves.
• Johnson & Johnson's Capital Expenditures stood at $607.0 million in 2022, then jumped by 161.78% to $1.6 billion in 2023, then rose by 1.45% to $1.6 billion in 2024, then rose by 13.96% to $1.8 billion in 2025, then plunged by 42.9% to $1.0 billion in 2026.
• The last three Capital Expenditures figures came in at $1.0 billion (Q1 2026), $1.8 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.